Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 2 years ago

Possible Interaction: Niacin and Laropiprant

supplement:

Niacin

Research Papers that Mention the Interaction

In the light of the results of HPS2-THRIVE study, we may hypothesize that the addition of laropiprant to niacin might be responsible for these negative effects.
Journal of Thrombosis and Thrombolysis  •  2015  |  View Paper
Laropiprant (LRPT) reduces flushing associated with niacin.
Cardiology  •  2009  |  View Paper
Laropiprant , an antagonist of the PGD2 receptor, DP1, is effective in reducing the flushing symptoms associated with extended‐release (ER) niacin and thereby improves the tolerability of niacin therapy for dyslipidemia.
Journal of clinical pharmacology  •  2009  |  View Paper
Lastly, laropiprant , an antagonist of the DP1 receptor of prostaglandin D2, is used in combination with niacin to suppress the niacin-induced vasodilation.9 Figure 1 Major pathways of arachidonic acid metabolism.
Journal of medicinal chemistry  •  2012  |  View Paper
The flushing associated with niacin which has previously affected patient compliance can now be significantly blocked with laropiprant (LRPT).
Expert opinion on pharmacotherapy  •  2012  |  View Paper
The favorable safety profile supports the use of LRP to achieve higher therapeutic dosing of niacin.
Therefore, it is time to collate available information to assess the safety and tolerability of combining niacin with LRP.
Expert opinion on drug safety  •  2012  |  View Paper
DP1 receptor antagonist laropiprant ) attenuates the niacin flush in animals and humans.
Current opinion in cardiology  •  2008  |  View Paper
In HPS2THRIVE, a combination of niacin with the prostaglandin receptor blocker laropiprant did not show any clinical benefit [7] .
Cardiology  •  2016  |  View Paper
AIM Cutaneous flushing with niacin varies between individuals and is substantially reduced by concomitant laropiprant.
Pharmacogenomics  •  2015  |  View Paper
Niacin commonly causes cutaneous flushing, which is partially alleviated by laropiprant , a selective antagonist of prostaglandin D2 at the DP1 receptor.
Journal of clinical pharmacy and therapeutics  •  2013  |  View Paper
Show More